Abstract:Cancer is one of the major causes of death worldwide and the development of multidrug resistance (MDR) in cancer cells is the principal cause of chemotherapy failure. To gain insights into the specific mechanisms of MDR in cancer cell lines, we developed a novel method for the combined analysis of recently published datasets on drug sensitivity and CRISPR loss-of-function screens for the same set of cancer cell lines. For our analysis, we first selected cell lines that consistently exhibit drug resistance across several classes of compounds. We then identified putative resistance genes for each class of compound and used inferred gene regulatory networks (GRNs) to study possible mechanisms underlying the development of MDR in the identified cancer cell lines. We show that the same method of analysis can also be used to identify cell lines that consistently exhibit resistance to the gene knockout effect of the CRISPR-Cas9 technique and to study the possible underlying mechanisms. In the GRN associated to the drug resistant cell lines, we identify genes previously associated with resistance (UHMK1, RALYL, MGST3, USP9X, and ESRG), genes for which an indirect association can be identified (SPINK13, LINC00664, MRPL38, and EMILIN3), and genes that are found to be overexpressed in non-resistant cancer cell lines (MRPL38, EMILIN3 and RALYL). In the GRNs associated to the CRISPR-Cas9 resistance mechanism, none of the identified genes has been previously reported in the admittedly sparse literature on the subject. However, some of these genes have a common role: APBB2, RUNX1T1, ZBTB7C, and ISX regulate transcription, while APBB2, BTG3, ZBTB7C, SZRD1 and LEF1 have a function in regulating proliferation, suggesting a role for these two pathways. While our results are specific for the lung cancer cell lines we selected for this work, our method of analysis can be applied to cell lines from other tissues and for which the required data is available.

A CRISPR interference strategy for gene expression silencing in multiple myeloma cell lines

An unbiased lncRNAs dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for Multiple Myeloma

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma

Pb1976: Crispr-Cas9 Knockout Screen Identifies Rna Modification Enzymes Essential For Cell Survival In Multiple Myeloma

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

siRNA Lipid-Polymer Nanoparticles Targeting E-Selectin and Cyclophilin A in Bone Marrow for Combination Multiple Myeloma Therapy

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions between Non-Coding RNAs in Cancer Cells

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Advances and Obstacles in Using CRISPR/Cas9 Technology for Non-Coding RNA Gene Knockout in Human Mesenchymal Stromal Cells

Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome‐scale CRISPR‐Cas9 screening in myeloma cells

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy

Facilitating Gene Editing in Human Lymphoma Cells Using Murine Ecotropic γ-Retroviruses

Fibroblast Growth Factor Receptor 3 Inhibition by Short Hairpin RNAs Leads to Apoptosis in Multiple Myeloma

High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells

Author Correction: Generation of a CRISPR Activation Mouse That Enables Modelling of Aggressive Lymphoma and Interrogation of Venetoclax Resistance